This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2019 The Authors Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. The correlation between STAT3 mutation and pSTAT3 expression was not significant (P = .07). Both univariate and multivariate analysis revealed that pSTAT3 expression was significantly associated with better overall survival and progression-free survival in the smoldering type of ATLL, whereas STAT3 mutation was not related to a line of clinical outcome. Collectively, our data show that only the lymphoma type showed a low prevalence of tumor cells positive for pSTAT3 expression, and raises the possibility that pSTAT3 expression is a novel biomarker to predict better prognosis in the smoldering type of ATLL.
pathological significance of this pathway. Clinical and morphological findings were reviewed in 116 cases with ATLL. The nuclear localizations of phosphorylated STAT3 (pSTAT3), pSTAT5, and pSTAT6 were analyzed by immunohistochemistry. Targeted sequencing was undertaken on the portion of STAT3 encoding the Src homology 2 domain. Expression of pSTAT3 was observed in 43% (50/116) of ATLL cases, whereas pSTAT5 and pSTAT6 were largely undetected. Cases with the lymphoma type showed significantly less frequent pSTAT3 expression (8/45, 18%) than those with the other subtypes (41/66, 62%; P < .001). STAT3 mutations were detected in 36% (10/28) and 19% (12/64) of cases with the smoldering and aggressive types of ATLL, respectively.
The correlation between STAT3 mutation and pSTAT3 expression was not significant (P = .07). Both univariate and multivariate analysis revealed that pSTAT3 expression was significantly associated with better overall survival and progression-free survival in the smoldering type of ATLL, whereas STAT3 mutation was not related to a line of clinical outcome. Collectively, our data show that only the lymphoma type showed a low prevalence of tumor cells positive for pSTAT3 expression, and raises the possibility that pSTAT3 expression is a novel biomarker to predict better prognosis in the smoldering type of ATLL.
| INTRODUC TI ON
Adult T-cell leukemia/lymphoma (ATLL) is a malignant peripheral Tcell neoplasm caused by human T-cell leukemia virus type I (HTLV-1).
1
According to the Shimoyama classification, ATLL is classified into 4 disease subtypes: smoldering, chronic, lymphoma, and acute.
2, 3 The acute, lymphoma, and chronic types, when accompanied by unfavorable prognostic factors (hypoalbuminemia, high serum blood urea nitrogen, or high serum lactate dehydrogenase), are regarded as aggressive forms of the disease, and generally have an adverse clinical course. 4 In contrast, the indolent type of ATLL, which includes the smoldering type and the chronic type without unfavorable factors, usually presents with a slower clinical course and progresses to an aggressive type of ATLL following additional genetic alterations. The JAK-STAT signaling pathway plays important roles in various critical cellular processes, including survival, proliferation, and differentiation. In this study, we determine the clinicopathological relevance of JAK-STAT pathway activation in patients with ATLL, with a particular emphasis on the impact of STAT3 mutation or pSTAT3 expression on the prognosis of the smoldering type. 
| MATERIAL S AND ME THODS

| Patients and samples
| Mutation analysis
Targeted deep sequencing was undertaken on exons 20 and 21 of the STAT3 gene, corresponding to the Src homology 2 (SH2) domain of STAT3, which is a mutation hotspot. 26 Genetic analysis of other genes associated with the JAK-STAT pathway was not undertaken in this study because of their very low mutation frequency. 26 In our analysis, DNA was extracted from FFPE samples with a QIAamp DNA FFPE Tissue Kit (catalog number 56404; Qiagen) and quantitated using a Qubit dsDNA HS Assay Kit (catalog number Q32854;
Thermo Fisher Scientific). Overhang PCR was carried out with
Trans Taq DNA Polymerase High Fidelity (catalog number AP131;
TransGen Biotech) and primers harboring adapter sequences. Each primer sequence utilized in this study is listed in Table S1 . Secondstep PCR was carried out using the Nextera XT Index Polymerase Kit After sequencing, each FASTQ file was processed using the Variant Studio software (Illumina). STAT3 variants were selected when they showed a variant allele frequency higher than 2% and more than 10 variant read-outs in at least 20 total reads. Only mutations already reported in COSMIC (http://cancer.sanger.ac.uk/cosmic) were considered to be significant STAT3 mutations.
| Clinicopathological evaluation and statistical analysis
Patients' clinicopathological characteristics were analyzed using Pearson's χ 2 or Fisher's 2-sided exact test. The Kaplan-Meier method was used to analyze patient survival data and the log-rank test was used to determine significant differences. To evaluate the prognostic impact of different variables, a Cox proportional hazards model was used for multivariate analysis. Overall survival (OS) was defined as the period from the day of diagnosis to the day of last follow-up or to the day of death from any cause. Progression-free survival (PFS)
in patients with indolent (smoldering)-type ATLL was defined as the period from the day of diagnosis to the day of progression to an aggressive type of ATLL. Patients still alive were censored at the last follow-up date. All statistical analyses were undertaken using Stata Software, release 13 (Stata Corporation). P < .05 was considered statistically significant. of the lymphoma type cases were positive ( Figure 1 ). These data indicated that pSTAT3 expression was significantly less common in cases with the lymphoma type than in those with the other types ( Table 2 , P < .001). Among the 42 cases with lymph node samples, 37 and 5 were diagnosed with the lymphoma and acute types, respectively. Fourteen percent (5/37) of cases with the lymphoma type showed pSTAT3 expression, whereas 60% (3/5) with the acute type showed pSTAT3 expression (P = .04). Therefore, the lower frequency of pSTAT3 expression observed in cases with the lymphoma type did not seem to be related to topographic location in the lymph nodes, but rather to the clinical ATLL subtype. Furthermore, the pleomorphic medium cell morphology was associated with more frequent pSTAT3 expression than the other morphologies (Table S4 , P = .02). This result might be explained by the fact that patients with (Figure 2 ).
| RE SULTS
| Clinicopathological characteristics of patients
Next, we analyzed the effects of disease progression on pSTAT3 expression. Fifty-five percent (21/38) of patients with the smoldering type of ATLL showed disease progression. In this group, pSTAT3 nuclear expression was observed in 43% (6/14) and 64% (9/14) of patients whose samples were obtained before and after progression, respectively. Among the 7 cases whose samples were obtained both before and after progression, the level of pSTAT3 expression changed from negative to positive in 2 cases, from positive to negative in 1 case, and was unchanged in 4 cases. Notably, 83% (5/6) of the cases who progressed to the lymphoma type showed significantly more frequent pSTAT3 expression than the cases with the lymphoma type who had not been previously diagnosed with the indolent type of ATLL (18%, 8/45; P < .01). Table 3 shows the association between patients' clinical features and pSTAT3 expression. The pSTAT3-positive group had better performance status (PS) than the pSTAT3-negative group. Regarding prognosis, the pSTAT3-positive group had significantly better OS than the pSTAT3-negative group ( Figure 3A) . This is likely due to the fact that more than half of the patients with the smoldering type were in the pSTAT3-positive group. Therefore, we also evaluated the prognostic impact of pSTAT3 expression separately in the aggressive and smoldering types. In this analysis, pSTAT3-positive patients with the smoldering type showed significantly better OS and PFS than pSTAT3-negative patients, whereas this association was not Notes: B symptoms refer to systemic symptoms of fever which come and go over several weeks, drenching night sweat, and unexplained weight loss at least 10% of body weight within the preceding 6 mo. Abbreviations: IL-2, interleukin-2; LDH, lactate dehydrogenase.
TA B L E 3 Clinical characteristics of adult T-cell leukemia/lymphoma cases with regard to phosphorylated STAT3 (pSTAT3) expression observed in patients with the aggressive type ( Figures 3B-D and S3 ).
Univariable analysis showed that positive pSTAT3 expression, age greater than 70 years, and iATL-PI had a trend to impact prognosis. In multivariable analysis, age greater than 70 years and positive pSTAT3 expression was associated with poor and favorable prognostic significance, respectively, for both OS and PFS in the patients with the smoldering type (Table 4 ).
| STAT3 mutation and its relationship with clinicopathological findings
Based 
| D ISCUSS I ON
The major findings in this study were that pSTAT3 positivity was substantially lower in patients with the lymphoma type than in those with other clinical subtypes of ATLL, and that pSTAT3 positivity could predict favorable prognosis in patients with the smoldering type of ATLL.
In our data, 40% of ATLL cases showed nuclear expression of pSTAT3, whereas pSTAT5 or pSTAT6 expression was rarely ob- Abbreviations: CI, confidence interval; HR, hazard ratio; iATL-PI, indolent ATLL prognostic index; neg., negative; OS, overall survival; PFS, progression-free survival; pos., positive; pSTAT3, phosphorylated STAT3; sIL-2, serum interleukin-2. 
45,46
In this study, we also observed that 29% (6/21) of cases with disease progression showed clinical features corresponding to the lymphoma type. In fact, the positive rate of pSTAT3 in these cases (5/6, 83%) was significantly higher than that in cases with the lymphoma type who had not been previously diagnosed with the indolent type Pautrier's microabscesses exaggerated tumor cell growth through the activation of the JAK-STAT pathway in CTCL. 49 The importance of such extracellular stimuli for JAK-STAT pathway activation was also found in ALK-negative anaplastic large cell lymphoma. 50 Further research, such as a comparative analysis of gene expression between cases with and without STAT3 mutation, is required to elucidate the mechanism of pSTAT3 expression. We also showed that pSTAT3 expression was significantly associated with better PS and favorable F I G U R E 4 Schematic representation of the 2 different oncogenic pathways involved in the lymphoma type of adult T-cell leukemia/ lymphoma (ATLL). Nuclear phosphorylated STAT3 (pSTAT3) expression is the distinguishing characteristic between the progressed lymphoma type (expresses pSTAT3, similar to acute and smoldering types) and de novo lymphoma type (does not express pSTAT3), suggesting the existence of at least 2 oncogenic molecular mechanisms. HTLV-1, human T-cell leukemia virus type I prognosis in the smoldering type of ATLL, whereas STAT3 mutation was not. This result suggests that pSTAT3 expression reflects the underlying molecular pathogenesis more directly than STAT3 mutation, at least in the smoldering type of ATLL. Multidisciplinary approaches, including pathological assessment, remain critical, even though precision medicine mainly based on comprehensive genomic analysis is rapidly being applied to clinical practice.
There are several limitations to this study. First, the molecular mechanisms underlying the difference in expression levels of pSTAT3 between the lymphoma type and other subtypes were not
clarified. According to a previous study, the lymphoma type of ATLL showed no genomic abnormalities or dysregulated gene expression that might have inhibited STAT3. 24 Ideally, experiments using cell lines derived from each subtype should be undertaken to address this issue. However, almost all established ATLL cell lines are derived from the acute type. Another limitation of this study is that it evaluated only FFPE tissue samples, and not peripheral blood samples.
Although further studies, including those analyzing samples obtained from peripheral blood, are required to reinforce our results, this study could highlight a pivotal role for STAT3 activation in distinct subtypes of ATLL.
In conclusion, in this study we reported in detail the clinicopathological significance of the JAK-STAT pathway in ATLL. Our data showed that pSTAT3 was mainly involved in the pathogenesis of the smoldering, chronic, and acute types of ATLL. Our results also showed that pSTAT3 expression, and not STAT3 mutation, predicted favorable clinical outcome exclusively in the smoldering type.
Collectively, this study sheds light on the molecular pathogenesis of ATLL, thereby highlighting pSTAT3 as a potentially novel biomarker for the prognosis of the smoldering type of ATLL.
